As reports surface that the UK’s national screening committee are set to reject proposals for any national prostate screening programme, experts warn that the decision, if followed through with, puts ...

Secondary endpoint data from the EMBARK trial support use of enzalutamide treatments in patients with high-risk biochemically recurrent prostate cancer.

NHS England has announced that men whose high-risk prostate cancer has not yet spread will be able to receive the drug, abiraterone.

Investigators trialed injection of an immune-stimulating substance (poly-ICLC) into the prostate gland using MRI-ultrasound fusion technology in patients scheduled to undergo radical prostatectomy.

In cases of clinical equipoise, the highest MMAI score quartile could guide selective treatment intensification among patients with high-risk nonmetastatic prostate cancer. An artificial ...

Thousands of men with incurable prostate cancer will be offered a lifeline after an about-turn on NHS treatment.

A bill moving through the Alabama legislature could remove financial barriers for men at high risk of developing prostate ...

We report the clinical outcomes of a randomized trial comparing prophylactic whole-pelvic nodal radiotherapy to prostate-only radiotherapy (PORT) in high-risk prostate cancer. This phase III, single ...

Dr. Nicholas James discusses why it is important to identify which patients with high-risk prostate cancer will truly benefit from intensified treatment. It is important to target intensified therapy ...

Chronically high levels of insulin and inflammation are key features of obesity and metabolic syndrome, which mediate cancer ...

An individual-patient meta-analysis sheds light on the optimal duration of androgen deprivation therapy in men with prostate cancer on definitive radiotherapy.